Opendata, web and dolomites

TRACER SIGNED

TRAF-STOP therapy to reduCe inflammation in athERosclerosis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRACER project word cloud

Explore the words cloud of the TRACER project. It provides you a very rough idea of what is the project "TRACER" about.

reduces    inhibition    molecule    found    mediators    majority    excellent    model    lowering    modeled    cd40    founders    underlying    animal    receptor    toxicology    events    ligand    signaling    patent    pass    valorise    bind    portfolio    small    cartesio    atherosclerotic    cd40l    binding    first    mini    hold    hypothesis    pursue    unaddressed    plan    clinical    thromboembolic    business    disease    interaction    prof    co    drug    virtual    stops    traf    inflammatory    implications    screening    stimulatory    solid    traf6    blocking    vast    bio    cardiovascular    ing    inhibitors    domain    diseases    characterizing    venture    company    treat    risk    ready    translational    relative    arteries    candidates    atherosclerosis    downstream    oral    termed    poc    lutgens    suppression    reduce    dyad    capital    force    25    seed    grant    driving    pipeline    poses    pig    therapeutics    significantly    tnf    investment    lipid    tested    mice    tolerated    start    treatment    therapeutic    scientific    despite    immune    hands   

Project "TRACER" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM 

Organization address
address: MEIBERGDREEF 15
city: AMSTERDAM
postcode: 1105AZ
website: www.amc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) coordinator 150˙000.00

Map

 Project objective

Atherosclerosis, the underlying cause of the majority of cardiovascular diseases, is a lipid driven, inflammatory disease of the large arteries. Despite a 25% relative risk reduction achieved by lipid-lowering treatment, the vast majority of atherosclerosis induced cardiovascular disease risk remains unaddressed. Therefore, characterizing mediators of the inflammatory aspect of atherosclerosis is a widely recognized scientific goal with great therapeutic implications. Blocking the co-stimulatory CD40L-CD40 dyad reduces atherosclerosis. However, long-term inhibition of CD40L or its receptor CD40 results in suppression of the immune system and poses a risk for thromboembolic events. Therefore, we focused on the downstream signaling pathways of CD40, and found that the interaction between CD40 and TNF-receptor-associated factor 6 (TRAF6) is the driving force for atherosclerosis. Using virtual ligand screening, we identified several small molecule inhibitors termed TRAF-STOPs that were modeled to bind to the CD40-binding domain of TRAF6. TRAF-STOPs significantly reduce (existing) atherosclerosis and treatment was well tolerated. The first toxicology results in mice show that there are no side effects. Here we pursue the hypothesis that TRAF-STOPs are excellent candidates to pass the translational pipeline towards a clinical application to treat atherosclerotic cardiovascular disease. Prof. Lutgens is one of the founders of the recently established start-up company Cartesio Therapeutics to be able to valorise our novel TRAF-STOPs. By the end of the PoC grant, we expect to have an oral drug available and to have completed toxicology and bio-distribution analysis in a large animal model (mini-pig) and have tested TRAF-STOPs in a pig model of atherosclerosis. This way, we hold a solid business case in our hands. The resulting business- and (pre-)clinical development plan and patent portfolio will then be ready for seed investment and venture capital funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRACER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRACER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  
lastchecktime (2022-08-08 18:52:51) correctly updated